KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Total Liabilities: 2018-2025

Historic Total Liabilities for Esperion Therapeutics (ESPR) over the last 8 years, with Sep 2025 value amounting to $815.4 million.

  • Esperion Therapeutics' Total Liabilities rose 19.15% to $815.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $815.4 million, marking a year-over-year increase of 19.15%. This contributed to the annual value of $732.5 million for FY2024, which is 10.86% up from last year.
  • Per Esperion Therapeutics' latest filing, its Total Liabilities stood at $815.4 million for Q3 2025, which was up 4.46% from $780.6 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Total Liabilities ranged from a high of $815.4 million in Q3 2025 and a low of $548.0 million during Q1 2021.
  • Its 3-year average for Total Liabilities is $691.6 million, with a median of $684.3 million in 2024.
  • Its Total Liabilities has fluctuated over the past 5 years, first spiked by 142.95% in 2021, then dropped by 1.76% in 2023.
  • Esperion Therapeutics' Total Liabilities (Quarterly) stood at $578.5 million in 2021, then decreased by 1.18% to $571.7 million in 2022, then rose by 15.58% to $660.8 million in 2023, then increased by 10.86% to $732.5 million in 2024, then rose by 19.15% to $815.4 million in 2025.
  • Its last three reported values are $815.4 million in Q3 2025, $780.6 million for Q2 2025, and $750.2 million during Q1 2025.